Bcl-w - Network of Cancer Research

Navitoclax (ABT-263) is an Orally Active Bcl-2 Inhibitor for Chronic Lymphocytic Leukemia Research

Louis Gilman March 6, 2023

Bcl-2 family proteins, known as B-cell lymphoma 2, are regulators of programmed cell death. Additionally, the bcl-2 family includes pro-apoptotic and anti-apoptotic proteins. Anti-apoptotic proteins refer to Bcl-2, Bcl-x (L),…

Gastric Cancer Leukemia

ABT-737 is a Selective and BH3 Mimetic Bcl-2, Bcl-xL and Bcl-w Inhibitor

Louis Gilman December 28, 2021

Bcl-2 protein family is a key regulator of apoptosis and a marker of B-cell lymphoma. Importantly, apoptosis is an important physiological process of selective cell clearance, involving a variety of…

Navitoclax (ABT-263) is an Orally Active Bcl-2 Inhibitor for Chronic Lymphocytic Leukemia Research

ABT-737 is a Selective and BH3 Mimetic Bcl-2, Bcl-xL and Bcl-w Inhibitor

You Missed

Erlotinib is an EGFR TKI for NSCLC and Pancreatic Cancer Research

Parsaclisib is an Orally Active PI3Kδ Inhibitor for B-cell Malignancies Research

Nilotinib is an Orally Active Bcr-Abl Tyrosine Kinase Inhibitor for CML Research

Temsirolimus is an mTOR Inhibitor for Kinds of Cancers Research